For: | Hu PH, Pan LH, Wong PTY, Chen WH, Yang YQ, Wang H, Xiang JJ, Xu M. 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma. World J Gastroenterol 2016; 22(21): 5033-5041 [PMID: 27275095 DOI: 10.3748/wjg.v22.i21.5033] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i21/5033.htm |
Number | Citing Articles |
1 |
Penghui Hu, Kaman So, Hongjie Chen, Qimou Lin, Meng Xu, Yiguang Lin. A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition. International Journal of Immunopathology and Pharmacology 2022; 36 doi: 10.1177/03946320221105134
|
2 |
Jiaming Zhou, Jiaxuan Liu, Tiejun Li, Qiang Zhong, Hongyu Yu. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion
and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK
Signaling Pathway. Current Cancer Drug Targets 2024; 24(8): 791 doi: 10.2174/0115680096254722231025110912
|
3 |
Penghui Hu, Hongjie Chen, Eileen M McGowan, Nina Ren, Meng Xu, Yiguang Lin. Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening. Human Gene Therapy Methods 2018; 29(1): 30 doi: 10.1089/hgtb.2017.104
|
4 |
Julie Bolcaen, Shankari Nair, Cathryn Driver, Tebatso Boshomane, Thomas Ebenhan, Charlot Vandevoorde. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals 2021; 14(7): 626 doi: 10.3390/ph14070626
|
5 |
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, Michael Mohr, Christoph Schliemann, Wolfgang E. Berdel, Lars Henning Schmidt. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers 2019; 11(5): 690 doi: 10.3390/cancers11050690
|
6 |
Christopher Montemagno, Gilles Pagès. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00584
|